Kineta is preparing to enter the clinic with a unique IO therapy that reprograms the tumor microenvironment (TME) by inhibiting VISTA, a protein mainly expressed on macrophages. In preclinical ...
The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...
The therapists listed above, who practice therapy in Vista, are trained to protect client confidentiality and privacy. In keeping with our high membership standards, these mental health ...
Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...
an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid tumors. KVA12123 cleared all six monotherapy dose levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback